What Race Has to Do With Pediatric Lymphoma

A new study from the University of Miami Miller School of Medicine shows that race may play a role in the survival rates of children and adolescents with Hodgkin lymphoma.

Specifically, researchers found that African-American pediatric patients with the condition are less likely to survive this type of cancer than their white or Hispanic peers.

"Little was known about the association between race, ethnicity and survival in the pediatric Hodgkin lymphoma population," said Dr. Joseph Panoff, radiation oncologist and lead author of the study.

Complex disparities

The study, which was the largest yet on racial and ethnic disparities among children with Hidgkin lymphoma, also found that Hispanic males had inferior survival rates compared with white males.

Lymphoma is the third most common form of cancer in both children and adults in the U.S., and outcomes for children are usually favorable with the right treatment.

More research on how diagnostic and treatment practices vary among races could shed more light on why African American children with Hodgkin lymphoma have lower survival rates.

"Clearly, racial and ethnic disparities persist in the pediatric Hodgkin lymphoma population despite modern treatment, particularly in Florida," Panoff added. "The underlying causes of these disparities are complex and need further explanation."

Source: University of Miami Miller School of Medicine

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap